Schmid Severin, Minnella Enrico Maria, Pilon Yohann, Rokah Merav, Rayes Roni, Najmeh Sara, Cools-Lartigue Jonathan, Ferri Lorenzo, Mulder David, Sirois Christian, Owen Scott, Shieh Benjamin, Ofiara Linda, Wong Annick, Sud Shelly, Baldini Gabriele, Carli Francesco, Spicer Jonathan
Division of Thoracic Surgery, Department of Surgery, McGill University Health Centre, Montreal, QC, Canada; Department of Thoracic Surgery, Medical Center - University of Freiburg, Freiburg, Germany.
Department of Anesthesia, McGill University Health Centre, Montreal, QC, Canada.
Clin Lung Cancer. 2022 Nov;23(7):593-599. doi: 10.1016/j.cllc.2022.05.004. Epub 2022 May 11.
Prehabilitation is well established for improving outcomes in cancer surgery. Combining prehabilitation with neoadjuvant treatments may provide an opportunity to rapidly initiate cancer-directed therapy while improving functional status in preparation for local consolidation. In this proof-of-concept study, we analyzed non-small-cell lung cancer patients who underwent simultaneous prehabilitation and neoadjuvant therapy.
We retrospectively analyzed all patients who underwent neoadjuvant treatment for non-small-cell lung cancer followed by curative intent surgery between 2015 and 2021. Patients who were screened for the prehabilitation program were identified. The screening included assessment of physical performance, nutritional status, and signs of anxiety and depression.
We identified a total of 141 patients who underwent neoadjuvant therapy. Twenty patients were screened to undergo a prehabilitation program. Four patients did not complete the exercise program (1 surgical intervention too soon, 1 drop-out after the first session, and 2 patients were deemed fit without intervention). The postoperative median length of stay was 2 days (range 1-18). Patients improved their 6-minute-walk test despite undergoing neoadjuvant treatment by a mean of 33 meters (± 50, P = .1). Self-reported functional status (DASI) showed significant improvement by a mean of 10 points (± 11, P = .03), and HADS-anxiety-score was significantly reduced after the prehabilitation program by a mean of 1.5 points (± 1, P = .005).
Neoadjuvant prehabilitation therapy is feasible and associated with encouraging results. The performance of all measures remains a logistic challenge. With multimodal strategies for lung cancer treatment becoming key to optimal outcomes, neoadjuvant prehabilitation therapy is a concept worthy of prospective multi-center evaluation.
术前康复已被充分证实可改善癌症手术的预后。将术前康复与新辅助治疗相结合,可能为迅速启动癌症导向治疗提供机会,同时改善功能状态,为局部巩固治疗做准备。在这项概念验证研究中,我们分析了同时接受术前康复和新辅助治疗的非小细胞肺癌患者。
我们回顾性分析了2015年至2021年间所有接受非小细胞肺癌新辅助治疗并随后进行根治性手术的患者。确定了接受术前康复计划筛查的患者。筛查包括身体机能、营养状况以及焦虑和抑郁症状的评估。
我们共确定了141例接受新辅助治疗的患者。20例患者被筛查接受术前康复计划。4例患者未完成锻炼计划(1例因手术干预过早,1例在第一期后退出,2例患者未干预即被认为身体状况良好)。术后中位住院时间为2天(范围1 - 18天)。尽管接受了新辅助治疗,患者的6分钟步行试验平均提高了33米(±50,P = 0.1)。自我报告的功能状态(DASI)平均显著改善了10分(±11,P = 0.03),并且在术前康复计划后,医院焦虑抑郁量表(HADS)焦虑评分平均显著降低了1.5分(±1,P = 0.005)。
新辅助术前康复治疗是可行的,且结果令人鼓舞。所有措施的实施仍然是一个后勤方面的挑战。随着肺癌治疗的多模式策略成为实现最佳预后的关键,新辅助术前康复治疗是一个值得进行前瞻性多中心评估的概念。